Qiagen N.V. (QIA.DE)
| Previous Close | 42.64 |
| Open | 42.35 |
| Bid | 0.00 x 48300 |
| Ask | 0.00 x 51100 |
| Day's Range | 42.35 - 43.10 |
| 52 Week Range | 39.94 - 49.37 |
| Volume | |
| Avg. Volume | 425,914 |
| Market Cap | 9.822B |
| Beta (5Y Monthly) | 0.38 |
| PE Ratio (TTM) | 33.48 |
| EPS (TTM) | 1.27 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jan 25, 2017 |
| 1y Target Est | 47.90 |
- Business Wire
QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results
VENLO, The Netherlands, March 13, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2022, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here.
- Zacks
QIAGEN (QGEN) to Develop CDx Test for TIBSOVO With New Pact
QIAGEN (QGEN) will develop a real-time in vitro PCR test that can be utilized to spot IDH1 gene mutations in AML patients in whole blood and bone marrow aspirates.
- Business Wire
QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug
VENLO, the Netherlands, March 09, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO®, an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia (AML).
